Skip to main content
. 2023 Feb 13;55(2):426–442. doi: 10.1038/s12276-023-00937-x

Table 3.

Factors associated with events of plaque instability.

Factor Crude hazard ratio on univariate analysis (95% CI) P value Adjusted hazard ratio on multivariate analysis (95% CI) P value
Age (per year increase) 1.015 (0.955–1.079) 0.630
Female 1.360 (0.274–6.750) 0.707
Hypertension 1.421 (0.339–5.959) 0.631
Diabetes mellitus 1.104 (0.222–5.488) 0.904
Dyslipidemia 28.650 (0.017–48008.246) 0.376
Obesity 1.086 (0.259–4.556) 0.910
Smoking 1.960 (0.448–7.867) 0.343
Family history of CAD 0.199 (0.047–0.840) 0.028 0.002 (0.000–0.766) 0.041
Systolic blood pressure 1.017 (0.988–1.046) 0.253
Heart rate 0.997 (0.959–1.037) 0.885
Pain to balloon time 0.941 (0.729–1.213) 0.639
MVD 0.879 (0.219–3.527) 0.856
Culprit LAD 3.657 (0.736–18.162) 0.113 512.950 (0.502-524347.409) 0.078
Creatinine 0.785 (0.194–3.183) 0.735
ANGPTL4 levels 0.422 (0.162–1.101) 0.078 0.199 (0.049-0.808) 0.024
Peak CK-MB 0.996 (0.984–1.009) 0.584
Peak troponin-I 0.973 (0.936–1.012) 0.167 0.863 (0.736-1.013) 0.072
hsCRP 1.195 (1.050–1.359) 0.007 1.178 (1.023-1.356) 0.023
Initial LVEF 0.999 (0.992–1.006) 0.830
Ticagrelor or prasugrel at discharge 1.017 (0.944–1.095) 0.662
Beta-blocker at discharge 1.878 (0.469–7.517) 0.373
ACEi or ARB at discharge 1.294 (0.261–6.421) 0.758
Aldosterone antagonist at discharge 0.041 (0.000–562.583) 0.511
Use of statin at discharge 0.047 (0.000–3631445.951) 0.742

ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin-II receptor blocker, CAD coronary artery disease, CI confidence interval, CK-MB creatine kinase-myocardial band isozyme, hsCRP high-sensitivity C-reactive protein, LAD left anterior descending, LVEF left ventricular ejection fraction, MVD multivessel disease.

Bold values indicates statistically significant p values less than 0.05 (<0.05).